Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for ANNX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2018. Start Trial.
Date Value
June 30, 2026 186.06M
March 31, 2026 204.53M
December 31, 2025 211.65M
September 30, 2025 161.44M
June 30, 2025 199.02M
March 31, 2025 243.79M
December 31, 2024 293.10M
September 30, 2024 331.56M
June 30, 2024 361.08M
March 31, 2024 262.40M
December 31, 2023 250.56M
September 30, 2023 156.84M
June 30, 2023 184.72M
March 31, 2023 214.86M
December 31, 2022 231.19M
September 30, 2022 260.60M
Date Value
June 30, 2022 168.04M
March 31, 2022 200.61M
December 31, 2021 231.91M
September 30, 2021 264.48M
June 30, 2021 295.34M
March 31, 2021 321.48M
December 31, 2020 344.28M
September 30, 2020 365.48M
June 30, 2020 117.18M
March 31, 2020 31.84M
December 31, 2019 43.53M
September 30, 2019 -91.76M
June 30, 2019 -81.89M
March 31, 2019
December 31, 2018 -64.20M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Marker Therapeutics, Inc. 12.17M
Krystal Biotech, Inc. 1.359B
Immix Biopharma, Inc. 228.92M
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B

Shareholders Equity (Quarterly) Related Metrics